文献速递呼吸衰竭与机械通气心脑血管急症重症综合管理与镇静镇痛

肺栓塞诊断策略对COPD急性加重住院患者临床结局的影响:一项随机临床试验

Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01
一句话结论在COPD急性加重住院患者中,常规诊疗基础上加做肺栓塞主动诊断策略(D-二聚体阳性则行CTPA)并未显著改善90天复合结局。

该研究为西班牙18家医院开展的随机临床试验,纳入746例因COPD急性加重住院的患者,随机分为常规诊疗加肺栓塞主动诊断策略组(D-二聚体检测,阳性则行CT肺血管造影,n=370)与常规诊疗组(n=367)。主要终点为90天内非致命性症状性静脉血栓栓塞、因COPD再入院或死亡的复合结局,干预组29.7% vs 对照组29.2%(绝对风险差0.5%,95%CI -6.2%至7.3%;RR 1.02,95%CI 0.82-1.28;非致命性新发或复发性VTE、COPD再入院、全因死亡及大出血等次要终点两组均无显著差异。研究表明该主动诊断策略并未改善复合健康结局,但研究可能不足以评估复合终点的各单独组分。

要点

  • 非致命性新发或复发性VTE:干预组0.5% vs 对照组2.5%,风险差-2.0%(95%CI -4.3%至0.1%),差异未达统计学显著。
  • 90天因COPD再入院:干预组25.4% vs 对照组22.9%,风险差2.5%(95%CI -3.9%至8.9%)。
  • 该研究可能把握度不足,无法评估复合结局各单独组分,不能据此否定主动诊断策略对特定亚组的潜在价值。

适用人群与场景

  • 因COPD急性加重住院的成人患者(西班牙18家医院,2014年9月至2020年7月随机,最终随访2020年11月)。
  • 共746例随机分入干预组(n=370)与对照组(n=367),737例(98.8%)完成试验;平均年龄70岁,女性195例(26%)。

诊断标准与关键阈值

  • 干预策略为D-二聚体检测,若阳性则行CT肺血管造影(CTPA)以诊断肺栓塞。

处置流程与药物剂量

  • 第一步:对因COPD急性加重住院的患者,在常规诊疗基础上进行D-二聚体检测。
  • 第二步:若D-二聚体阳性,则行CT肺血管造影(CTPA)以诊断肺栓塞。
  • 对照组仅接受常规诊疗(未额外进行上述主动诊断策略)。
  • 原文未提及具体药物剂量、给药途径、频次或疗程。

红旗征与不能漏的情况

  • 原文未提及特定的红旗征或需立即处理的情况。

研究设计与关键结果

  • 研究类型:随机临床试验,西班牙18家医院,样本量746例(干预组370例,对照组367例),平均年龄70岁,女性26%。
  • 干预:常规诊疗加肺栓塞主动诊断策略(D-二聚体检测,阳性则CTPA) vs 常规诊疗。
  • 关键次要终点:非致命性新发或复发性VTE 0.5% vs 2.5%(风险差-2.0%,95%CI -4.3%至0.1%);90天COPD再入院25.4% vs 22.9%(风险差2.5%,95%CI -3.9%至8.9%);全因死亡6.2% vs 7.9%(风险差-1.7%,95%CI -5.7%至2.3%)。

证据类型、等级与局限

  • 证据类型:随机临床试验(RCT)。
  • 局限:原文指出研究可能把握度不足,无法评估复合结局的各单独组分。

对床旁实践的改变

  • 在因COPD急性加重住院的患者中,常规诊疗基础上加做肺栓塞主动诊断策略(D-二聚体阳性则CTPA)并未显著改善90天复合结局(VTE、COPD再入院或死亡),不改变当前对这类患者常规进行肺栓塞主动筛查的做法。
  • 该策略使非致命性新发或复发性VTE从2.5%降至0.5%(风险差-2.0%,95%CI -4.3%至0.1%),但差异未达统计学显著,不能据此推荐常规筛查。
  • 大出血发生率两组均为0.8%,主动诊断策略未增加大出血风险。
  • 原文未提及适用与不适用人群的进一步细分,也未提及常见陷阱。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Active search for pulmonary embolism (PE) may improve outcomes in patients hospitalized for exacerbations of chronic obstructive pulmonary disease (COPD).

OBJECTIVE: To compare usual care plus an active strategy for diagnosing PE with usual care alone in patients hospitalized for COPD exacerbation.

DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial conducted across 18 hospitals in Spain. A total of 746 patients were randomized from September 2014 to July 2020 (final follow-up was November 2020).

INTERVENTIONS: Usual care plus an active strategy for diagnosing PE (D-dimer testing and, if positive, computed tomography pulmonary angiogram) (n = 370) vs usual care (n = 367).

MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of nonfatal symptomatic venous thromboembolism (VTE), readmission for COPD, or death within 90 days after randomization. There were 4 secondary outcomes, including nonfatal new or recurrent VTE, readmission for COPD, and death from any cause within 90 days. Adverse events were also collected.

RESULTS: Among the 746 patients who were randomized, 737 (98.8%) completed the trial (mean age, 70 years; 195 [26%] women). The primary outcome occurred in 110 patients (29.7%) in the intervention group and 107 patients (29.2%) in the control group (absolute risk difference, 0.5% [95% CI, -6.2% to 7.3%]; relative risk, 1.02 [95% CI, 0.82-1.28]; P = .86). Nonfatal new or recurrent VTE was not significantly different in the 2 groups (0.5% vs 2.5%; risk difference, -2.0% [95% CI, -4.3% to 0.1%]). By day 90, a total of 94 patients (25.4%) in the intervention group and 84 (22.9%) in the control group had been readmitted for exacerbation of COPD (risk difference, 2.5% [95% CI, -3.9% to 8.9%]). Death from any cause occurred in 23 patients (6.2%) in the intervention group and 29 (7.9%) in the control group (risk difference, -1.7% [95% CI, -5.7% to 2.3%]). Major bleeding occurred in 3 patients (0.8%) in the intervention group and 3 patients (0.8%) in the control group (risk difference, 0% [95% CI, -1.9% to 1.8%]; P = .99).

CONCLUSIONS AND RELEVANCE: Among patients hospitalized for an exacerbation of COPD, the addition of an active strategy for the diagnosis of PE to usual care, compared with usual care alone, did not significantly improve a composite health outcome. The study may not have had adequate power to assess individual components of the composite outcome.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02238639.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Jiménez D, Agustí A, Tabernero E, et al. Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation: A Randomized Clinical Trial. JAMA. 2021. PMID: 34609451. doi:10.1001/jama.2021.14846

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。